Lannett Appoints New CEO
Lannett, a Philadelphia-headquartered generic drug manufacturer, has appointed Timothy C. Crew as the company’s chief executive officer (CEO), effective January 2, 2018.
The board of directors intends to appoint Crew as a director of the company after completion of its 2018 annual meeting of stockholders. Crew will succeed Arthur Bedrosian, who will continue to serve as CEO until Crew joins the company.
Crew has more than 25 years of experience in the generic and branded pharmaceutical industries, most recently serving as CEO of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017. Previously, he worked for eight years at Teva Pharmaceuticals, where he served as senior vice president and commercial operating officer of the North American Generics division. Before that, he was Teva’s vice president, alliances and business development. From 2001 to 2004, Crew was executive vice president, North America, for Dr. Reddy’s Laboratories. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development, and strategic planning.